Corcept Therapeutics Reports Q1 2025 Financial Results

Corcept Therapeutics ( (CORT) ) has provided an update.

On May 5, 2025, Corcept Therapeutics announced its financial results for the first quarter of 2025, reporting a revenue of $157.2 million, an increase from $146.8 million in the same period last year. Despite a record number of prescriptions, the company’s net income per share decreased due to initial fulfillment issues by its specialty pharmacy vendor. The company reiterated its 2025 revenue guidance of $900-$950 million. Corcept’s clinical development highlights include progress towards FDA approval for relacorilant in hypercortisolism and upcoming NDA submissions for relacorilant in platinum-resistant ovarian cancer. The company is also advancing studies in ALS and MASH, with significant findings from its DAZALS study showing improved survival rates for ALS patients on dazucorilant.

Spark’s Take on CORT Stock

According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.

Corcept Therapeutics scores well due to its strong financial performance and positive technical indicators. While the valuation is a concern due to its high P/E ratio, the earnings call reveals a strong growth outlook, supported by substantial cash reserves and advancements in its drug pipeline. The legal challenges and operational issues are minor setbacks in an otherwise strong profile.

To see Spark’s full report on CORT stock, click here.

More about Corcept Therapeutics

Corcept Therapeutics Incorporated is a commercial-stage company focused on the discovery and development of medications that modulate the effects of the hormone cortisol to treat serious endocrinologic, oncologic, metabolic, and neurologic disorders.

YTD Price Performance: 45.63%

Average Trading Volume: 1,604,499

Technical Sentiment Signal: Sell

Current Market Cap: $7.68B

Learn more about CORT stock on TipRanks’ Stock Analysis page.